-
The greatest challenge for any potentially mortal disorder is to prove that therapeutic interventions reduce not only disease-specific mortality, but also all-cause mortality.
-
-
-
Most cases of thrombocytopenia seen are expected. Patients are known to have hematological disease or are receiving chemotherapy. At times, however, the physician is confronted with an unexpected laboratory finding in an asymptomatic patient, or with a patient who is bleeding. The challenge, as usual, is to determine the need for acute treatment and the appropriate disposition.
-
Stop smoking drug Chantix rates stronger warning from FDA; Type 2 diabetes surgery on the way?; Vytorin study inconclusive; Influenza A virus found resistant to Tamiflu; FDA actions.
-
Duct tape is no more effective than moleskin for the treatment of common warts. Occlusion therapy with both for 7 days will give resolution in just over 20% of patients.
-
Increasing use of CT scans has led to an increase of radiation exposure to its recipients, potentially causing up to 2% of new cancers, especially in children.
-
The FDA has approved extended release niacin plus simvastatin as a combination product.
-
Does Published Evidence Reflect the Whole Story?, Vitamin E levels and Physical Decline with Aging, Effort, Efficacy, and Effectiveness
-
The onset of dementia heralds death in about 41/2 years.
